Coherus Oncology

CHRS · NASDAQ

$1.00+$0.0413 (+4.31%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.9587

Latest news

Press releaseSep 23, 9:30 AM ETGlobe Newswire
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
NewsAug 17, 5:37 PM ET
Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets
Press releaseAug 17, 5:33 PM ETGlobe Newswire
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Press releaseAug 5, 4:28 PM ETGlobe Newswire
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJun 23, 2:00 PM ETGlobe Newswire
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Press releaseMay 14, 9:00 AM ETPRNewswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Press releaseMay 11, 4:05 PM ETGlobe Newswire
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 11, 7:11 AM ET
Earnings Scheduled For May 11, 2026
NewsMar 30, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsMar 9, 4:18 PM ET
Insights into Coherus Oncology Q4 Earnings
Press releaseMar 9, 4:15 PM ETGlobe Newswire
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
NewsMar 9, 7:11 AM ET
Earnings Scheduled For March 9, 2026
NewsMar 6, 11:00 AM ET
Coherus BioSciences's Earnings Outlook
NewsFeb 13, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseJan 27, 10:50 AM ETPRNewswire
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
Press releaseJan 16, 8:00 AM ETPRNewswire
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Press releaseJan 12, 10:14 AM ETGlobe Newswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Press releaseJan 5, 9:30 AM ETGlobe Newswire
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Press releaseDec 8, 8:30 AM ETGlobe Newswire
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Press releaseNov 7, 9:00 AM ETGlobe Newswire
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsNov 5, 3:03 PM ET
Coherus BioSciences's Earnings Outlook
NewsSep 4, 10:05 AM ETAvi Kapoor
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
NewsJul 3, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsMay 13, 8:10 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMay 9, 4:05 PM ET
Earnings Preview: Coherus BioSciences
NewsNov 7, 11:31 AM ET
12 Health Care Stocks Moving In Thursday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings Scheduled For May 11, 2026

12 Health Care Stocks Moving In Monday's After-Market Session

Insights into Coherus Oncology Q4 Earnings

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For March 9, 2026

Coherus BioSciences's Earnings Outlook

12 Health Care Stocks Moving In Friday's Pre-Market Session

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Earnings Scheduled For November 6, 2025

Coherus BioSciences's Earnings Outlook

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Earnings Preview: Coherus BioSciences

12 Health Care Stocks Moving In Thursday's Intraday Session